research – 第 2 页

Hokkaido University and NEC conclude an agreement for developing spatial sensing to combat the spread of illness

June 28, 2022

TOKYO, Jun 28, 2022 - (JCN Newswire via SEAPRWire.com) - Hokkaido University and NEC Corporation (TSE: 6701) have concluded a collaborative agreement to promote the realization of a "safe and secure society through spatial sensing"(1) that helps to prevent the spread of illness.In recent years, COVID-19 has had a devastating impact on people's lives and economic activities throughout the world. Moreover, in the future, it is possible that additional pandemics may occur due to known viruses or currently unknown viruses. In response, Hokkaido University and NEC aim to offer virus visualization services based on spatial sensing technologies developed through collaborative research, and to link these with measures for business continuity planning (BCP) in the event of a pandemic.Background on the agreementHokkaido University is a multi-disciplinary education and research organization that includes undergraduate, graduate, research laboratories and university hospitals. The university supports interdisciplinary research, such as collaborative research that spans multiple departments and facilities across one of the largest university campuses in Japan.NEC proposes digital transformation (DX) that can contribute to solving social issues with cutting-edge digital technologies, such as world-class biometric identification technologies and proprietary AI technologies, in addition to the industry and operational know-how that it has cultivated over many years.To date, Hokkaido University and NEC have been conducting collaborative research(2) on the detection of viruses with biosensors(3) using aptamers(4) and collaborative research on virus aerosol collection methods(5). Based on these initiatives, Hokkaido University and NEC aim to further contribute to society by expanding this collaborative research.Collaboration details1. Establishment of technologies for detection of viruses in the air through collaborative research currently underway2. Verification of spatial sensing services through implementation of virus detection technology on campus and networking of spatial information3. New co-creation of spatial sensing that makes use of technologies possessed by both parties4. Expansion beyond campus as part of contributing to societyFuture initiativesThrough ongoing collaborative research, Hokkaido University and NEC will establish technologies for the detection of known viruses and efficient aerosol collection, aiming to conduct demonstration tests and implement these technologies on campus by fiscal 2023. Going forward, Hokkaido University and NEC seek to ensure safe, secure, and comfortable conditions by providing spatial sensing services that combine virus detection information with other spatial information to students and other campus visitors.(1) Spatial sensing: A system that measures, collects, analyzes and visualizes the environmental conditions of a space by various means (CO2 measurement sensors, virus detectors, cameras, etc.) and communication networks, and provides the results to users.(2) Collaborative research on virus detection: Collaborative research on virus measurement methods between the Hokkaido University International Institute for Zoonosis Control and NEC.(3) Biosensor: Sensors that can detect viruses by combining aptamer technologies and sensor technologies.(4) Aptamer: Nucleic acids (DNA and RNA) that recognize the spatial structure of a particular target molecule, such as a virus or protein, and specifically bind to it. It can be artificially produced by the SELEX technique of finding a sequence that binds strongly only to the inspection object.Reference: www.nec-solutioninnovators.co.jp/en/rd/thema/aptamer/index.html(5) Collaborative research on virus aerosol collection methods: Collaborative research in the fields of spatial design and aerosol collection methods between the Faculty of Engineering, Division of Architecture, Research Group of Architectural and Environmental Design, Laboratory of Environmental Space Design, Hokkaido University and NEC.About Hokkaido UniversityFounded in 1876 as Sapporo Agricultural College, Hokkaido University is one of the oldest, largest, and most prestigious universities in Japan. Boasting one of the largest campuses in the country, Hokkaido University houses cutting-edge research facilities, a university hospital, and a number of field research centers -- including one of the world's largest research forests. Today, our researchers in the social and natural sciences, as well as in the humanities, are working towards the advancement of human knowledge and resolution of global issues through their outstanding work. www.global.hokudai.ac.jp/About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at www.nec.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Novotech Receives CRO Leadership Award for Exceeding Customer Expectations

June 23, 2022

CHICAGO, IL, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was awarded a prestigious Clinical Leader and Life Science Leader CRO Leadership Award for exceeding customer expectations, at Drug Information Association 2022 (DIA 2022).Novotech CEO Dr. John Moller said the company was extremely pleased to receive this award for the second consecutive year. "Receiving this recognition from our clients is incredibly important to us and is an endorsement of our service delivery model that is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem solving, ownership and flexibility, and our investments in data and technology ensure clients have real time access to trial performance."Book a meeting with one of the Novotech experts at DIA here. https://novotech-cro.com/contactClinical Leader and Life Science Leader working with Industry Standard Research (ISR), selected Novotech for the CRO Leadership Award.According to the CRO Leadership Award research team: "The awards are based on customer feedback. Winning CROs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. Primary market research by ISR Reports is the basis of the awards. Sponsors provide ratings of CROs based on recent outsourced projects. This experiential feedback is analyzed by sponsor company size to reveal leading CROs in different performance categories."Ed Miseta, Chief Editor for Clinical Leader said: "Selecting the right CRO can make or break your project. It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. Regardless of whether you are concerned about compatibility, capabilities, expertise, quality, or reliability. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. We are grateful to our colleagues at ISR Reports for conducting the research necessary to produce these awards. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for the work ethic they exhibit in consistently meeting the needs of their drug development clients."Kevin Olson, CEO of Industry Standard Research said: "Industry Standard Research (IRS) continues to consider it an honor to provide the primary market research data for Life Science Leader and Clinical Leader's CRO Leadership Awards. ISR's stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research. This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enable users of ISR's market research to make confident business decisions based on the experiences of their industry peers."Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said Novotech's Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions. "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."About Novotech Health Holdings Pte Ltd ("Novotech")Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)